Hutchin Hill Capital’s Biogen BIIB Stock Holding History

Hutchin Hill Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10,000	Closed	-$2.84M	–	891
2016 Q4	$2.84M	Buy	10,000 +5,000	+100%	+$1.48M	0.1%	266
2016 Q3	$1.56M	Buy	+5,000	New	+$1.48M	0.03%	290

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Hutchin Hill Capital's BIIB Position: Q3 2017 in Review

Hutchin Hill Capital sold out of Biogen (BIIB) in Q3 2017, closing a stake of 800 shares — an estimated $217K sold.

Hutchin Hill Capital first reported a position in BIIB in Q2 2013 and held it in 10 quarters. The position peaked at $4.98M in Q4 2013. 1,014 funds tracked by Wall St. Rank hold BIIB as of Q3 2017.

Hutchin Hill Capital reported no remaining Biogen position as of Q3 2017 after selling out during the quarter.
Hutchin Hill Capital sold 800 Biogen shares in Q3 2017, an estimated $217K.
Hutchin Hill Capital first reported a position in Biogen in Q2 2013 and held it in 10 quarters.
Hutchin Hill Capital's Biogen position peaked at $4.98M in Q4 2013.
1,014 funds tracked by Wall St. Rank held Biogen as of Q3 2017.

Based on Hutchin Hill Capital's 13F filing for Q3 2017, filed 14 Nov 2017.